Roche Holding AG ADR Stock
€35.40
Your prediction
Roche Holding AG ADR Stock
Pros and Cons of Roche Holding AG ADR in the next few years
Pros
Cons
Performance of Roche Holding AG ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Roche Holding AG ADR | -0.270% | 4.396% | -3.721% | 5.424% | 9.405% | -9.883% | - |
Novartis AG ADR | 0.000% | -0.476% | 0.000% | 9.310% | 14.583% | 46.770% | 33.666% |
Bayer AG ADR | 3.130% | 0.000% | -7.692% | -45.902% | -23.256% | -41.071% | -60.241% |
Astrazeneca ADR | 0.000% | -3.401% | -7.792% | 13.600% | 15.447% | 49.789% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Roche Holding AG (RHHBY), a multinational healthcare company based in Switzerland, stands strong with its broad and diversified portfolio. A closer look into Roche's financial statements prominently reveals a robust business model underpinned by substantial revenues and a profitable margin.
Observing Roche's income statements over the past three years, the figures showcase an impressive gross profit with a steady upward trend. This consistency strongly indicates a robust operating model and proficient managerial efficiency. With increasing net income, the company seems to have experienced notable business and financial growth, reinforcing the credibility of the investment.
Roche also earns recognition for its significant investment in research and development, crucial for pharmaceutical companies. The data reveals a substantial annual expenditure, reflecting Roche's commitment to future growth and revolutionizing pharmaceutical breakthroughs, leading to a sustainable competitive advantage.
Comments
News
Why Roche Holdings Stock Withered on Wednesday
For the second trading session in less than a week, Roche Holding (OTC: RHHBY) stock really took it on the chin Wednesday. Dispiriting news about its investigational obesity drug was the culprit
Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer)
The diabetes and obesity care markets are under disruption. Glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, Wegovy, Mounjaro, and Zepbound have catapulted in popularity.
The thing
Here's Why Eli Lilly Stock Dropped 12% Last Month
Shares of Eli Lilly (NYSE: LLY) fell 20% in July, according to data from S&P Global Market Intelligence. The pharmaceutical stock tumbled after one of the company's competitors announced promising